What's new? Log in Free sign up

Silo Pharma (SILO)

Company Profile

Company profile

Ticker

SILO

Exchange

Website

CEO

Mr. Eric Weisblum

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Teva Pharmaceutical Industries Limited • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb • Viatris • AbbVie • Bausch Health Companies ...

Former names

Gold Swap Inc, Point Capital, Inc., Uppercut Brands, Inc.

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

IRS number

273046338

SILO stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

Silo Pharma Issues Letter to Shareholders Detailing Development Progress and Potential for Lead Assets Targeting PTSD and Chronic Pain

Submission of Matters to a Vote of Security Holders

Quarterly report

12 Nov 24

Additional proxy soliciting materials

Annual report to shareholders

Additional proxy soliciting materials

Definitive proxy

NOVEL THERAPEUTICS FOR UNMET MEDICAL NEEDS Investor Presentation September 2024

Latest ownership filings

View all

RENAISSANCE TECHNOLOGIES LLC

RENAISSANCE TECHNOLOGIES LLC

INTRACOASTAL CAPITAL, LLC

INTRACOASTAL CAPITAL, LLC

Financial summary

Financial statements Chart SILO financial data

Quarter (USD)	Sep 24	Jun 24	Mar 24	Dec 23
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	4.86 mm	4.86 mm	4.86 mm	4.86 mm	4.86 mm	4.86 mm
Cash burn (monthly)	(no burn)	(no burn)	336.69 k	338.01 k	448.83 k	318.87 k
Cash used (since last report)	n/a	n/a	1.72 mm	1.73 mm	2.29 mm	1.63 mm
Cash remaining	n/a	n/a	3.14 mm	3.13 mm	2.57 mm	3.23 mm
Runway (months of cash)	n/a	n/a	9.3	9.3	5.7	10.1

Beta Read what these cash burn values mean

Financial data from Silo Pharma earnings reports.

Institutional ownership, Q3 2024

SILO institutional ownership history Ownership history

11.9% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	8	6	+33.3%
Opened positions	6	3	+100.0%
Closed positions	4	7	-42.9%
Increased positions	2	0	NEW
Reduced positions	0	1	EXIT

13F shares	Current	Prev Q	Change
Total value	327.15 mm	42.21 mm	+675.1%
Total shares	532.19 k	277.40 k	+91.8%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Intracoastal Capital	235.53 k	$817.00 k	+21.8%
Renaissance Technologies	227.01 k	$249.71 mm	NEW
Geode Capital Management	30.76 k	$33.84 mm	+90.1%
Vanguard	16.33 k	$17.97 mm	NEW
STT State Street	12.50 k	$13.75 mm	NEW
Federation des caisses Desjardins du Quebec	6.00 k	$6.60 mm	NEW
Tower Research Capital	4.06 k	$4.47 mm	NEW
JPM JPMorgan Chase & Co.	1.00	$1.00 k	NEW
Proequities	0.00	$0.00

Largest transactions	Shares	Bought/sold	Change
Renaissance Technologies	227.01 k	+227.01 k	NEW
Intracoastal Capital	235.53 k	+42.18 k	+21.8%
Virtu Financial	0.00	-41.85 k	EXIT
Financial Advocates Investment Management	0.00	-23.94 k	EXIT
Vanguard	16.33 k	+16.33 k	NEW
Geode Capital Management	30.76 k	+14.58 k	+90.1%
STT State Street	12.50 k	+12.50 k	NEW
Federation des caisses Desjardins du Quebec	6.00 k	+6.00 k	NEW
Tower Research Capital	4.06 k	+4.06 k	NEW
Redwood Wealth Management	0.00	-2.00 k	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

SILO insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
13 Dec 24	Weisblum Eric	Common Stock	Buy	Acquire P	No	No	0.8387	2,500	2.10 k	187,932
22 Nov 24	Weisblum Eric	Common Stock	Buy	Acquire P	No	No	0.9	2,500	2.25 k	185,432
20 Nov 24	Weisblum Eric	Common Stock	Buy	Acquire P	No	No	0.95	2,500	2.38 k	182,932
12 Jun 24	Weisblum Eric	Common Stock	Buy	Acquire P	No	No	1.11	4,438	4.93 k	180,432
11 Jun 24	Weisblum Eric	Common Stock	Buy	Acquire P	No	No	1.08	562	606.96	175,994
5 Apr 24	Weisblum Eric	Common Stock	Buy	Acquire P	No	No	2.03	400	812.00	175,432
4 Apr 24	Weisblum Eric	Common Stock	Buy	Acquire P	No	No	1.96	600	1.18 k	175,032
1 Apr 24	Weisblum Eric	Common Stock	Buy	Acquire P	No	No	1.91	1,100	2.10 k	174,432
28 Mar 24	Weisblum Eric	Common Stock	Buy	Acquire P	No	No	1.94	3,408	6.61 k	173,332

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Silo Pharma Granted U.S. Patent For Novel Intranasal Post-Traumatic Stress Disorder Treatment Titled "Pharmacological Prophylactics Against Stress-Induced Affective Disorders In Females"

Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that the U.S. Patent and Trademark

Silo Pharma Files Provisional Patent Application For SPC-15 Combination Treatment

SPC-15 combination treatment shows enhanced efficacy in combating stress-induced psychiatric disorders

Silo Pharma's SP-26 Implant Shows Early Results in Chronic Pain and Fibromyalgia Study

Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced a positive update from an ongoing study

Silo Pharma Announces Provisional Patent Filing For SPC-15 Targeting NMDARs And 5-HT4Rs For Stress-Induced Psychiatric Disorders; Advances Collaboration With Columbia University

12 Health Care Stocks Moving In Friday's Pre-Market Session

Press releases

From Benzinga Pro

Silo Pharma Granted U.S. Patent for Novel Intranasal Post-Traumatic Stress Disorder Treatment

SARASOTA, FL, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today

Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for Innovative SPC-15 Combination Treatment

SPC-15 combination treatment shows enhanced efficacy in combating stress-induced psychiatric disorders SARASOTA, FL, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a

Silo Pharma Announces Positive Initial Pharmacokinetic, Safety, and Tolerability Study of SP-26 for Chronic Pain and Fibromyalgia

No serious side effects or discomfort observed Final safety and absorption data expected in March 2025 SARASOTA, FL, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (NASDAQ:SILO) ("Silo" or the "Company"), a

Silo Pharma Advances Intellectual Property Portfolio with Provisional Patent Filing for PTSD Treatment

Silo Pharma Issues Letter to Shareholders Detailing Development Progress and Potential for Lead Assets Targeting PTSD and Chronic Pain

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.